Hologic Inc.
Hologic Acquired by Blackstone and TPG; Joe Almeida Named CEO
Summary
Hologic, Inc. has been acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, resulting in Hologic becoming a private company. The acquisition includes significant investments from ADIA and GIC. José (Joe) E. Almeida has been appointed as the new Chief Executive Officer, effective immediately. Hologic's common stock has ceased trading and will be delisted from the Nasdaq Stock Market. The transaction was approved by Hologic stockholders on February 5, 2026. Shareholders will receive $76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to $3 per share in two payments, contingent on achieving certain global revenue goals for Hologic's Breast Health business in fiscal years 2026 and 2027.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement